drugset / Trial / NCT05772676

The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting

NCT05772676

Phase 4 Unknown 400 enrolled Hospital General Tlahuac
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen

Timeline

Start
2022-12-01
Primary completion
2023-01-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Subject Aprepitant Other / unclassified 125 mg Oral

Indications